Kreitzer Anatol
Known title: Chief Discovery OfficerCIK: 0002021238
Associated companies
Transaction History
| MPLT | ▲ Buy | Grant | 6,020 | $0 | 8/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 2,833 | $105K | 7/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 14,140 | $533K | 7/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 200 | $8K | 7/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 7,464 | $274K | 7/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 1,592 | $60K | 7/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 5,545 | $200K | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 4,510 | $167K | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 8,346 | $242K | 4/27/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 29,255 | $867K | 4/27/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 7,821 | $239K | 4/27/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 3,316 | $88K | 4/15/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 6,020 | $0 | 2/5/2026 | View on chart |
| MPLT | ▼ Sell | Tax Withholding | 42,099 | $757K | 1/27/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 35,953 | $0 | 10/27/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MapLight Therapeutics Shares Fall 34.8% in Four Weeks
MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.
MapLight Therapeutics Shares Fall 34.8% in Four Weeks. MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.